These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 16404503)

  • 21. Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.
    Van Peer A; Snoeck E; Huang ML; Heykants J
    Eur J Drug Metab Pharmacokinet; 1993; 18(1):49-59. PubMed ID: 8335039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives.
    Danhof M; Mandema JW; Hoogerkamp A; Mathôt RA
    Eur J Drug Metab Pharmacokinet; 1993; 18(1):41-7. PubMed ID: 8335038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling the dose-response relationship: the fair share of pharmacokinetic and pharmacodynamic information.
    González-Sales M; Nekka F; Tanguay M; Tremblay PO; Li J
    Br J Clin Pharmacol; 2017 Jun; 83(6):1240-1251. PubMed ID: 28035697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
    Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
    Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diversity of mechanism-based pharmacodynamic models.
    Mager DE; Wyska E; Jusko WJ
    Drug Metab Dispos; 2003 May; 31(5):510-8. PubMed ID: 12695336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.
    Jacqmin P; Snoeck E; van Schaick EA; Gieschke R; Pillai P; Steimer JL; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):57-85. PubMed ID: 17051439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and future directions of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling and simulation: population approach group in Europe 19th annual meeting.
    Kloft C; Poggesi I
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1599-604. PubMed ID: 20969486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic/pharmacodynamic modeling in drug research and development.
    Derendorf H; Lesko LJ; Chaikin P; Colburn WA; Lee P; Miller R; Powell R; Rhodes G; Stanski D; Venitz J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1399-418. PubMed ID: 11185661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.
    Wu H; Huang Y; Acosta EP; Park JG; Yu S; Rosenkranz SL; Kuritzkes DR; Eron JJ; Perelson AS; Gerber JG
    J Pharmacokinet Pharmacodyn; 2006 Aug; 33(4):399-419. PubMed ID: 16583266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative structure-pharmacokinetic/pharmacodynamic relationships.
    Mager DE
    Adv Drug Deliv Rev; 2006 Nov; 58(12-13):1326-56. PubMed ID: 17092600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The place of simultaneous pharmacokinetic pharmacodynamic modeling in new drug development: trends and perspectives.
    Girard P; Nony P; Boissel JP
    Fundam Clin Pharmacol; 1990; 4 Suppl 2():103s-115s. PubMed ID: 2093621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ; Lalonde RL
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract]   [Full Text] [Related]  

  • 35. A review on estimation of stochastic differential equations for pharmacokinetic/pharmacodynamic models.
    Donnet S; Samson A
    Adv Drug Deliv Rev; 2013 Jun; 65(7):929-39. PubMed ID: 23528446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of microdialysis for pharmacokinetic-pharmacodynamic modelling.
    Höcht C; Opezzo JA; Bramuglia GF; Taira CA
    Expert Opin Drug Discov; 2006 Sep; 1(4):289-301. PubMed ID: 23495900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.
    Danhof M; Alvan G; Dahl SG; Kuhlmann J; Paintaud G
    Pharm Res; 2005 Sep; 22(9):1432-7. PubMed ID: 16132354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
    Dartois C; Brendel K; Comets E; Laffont CM; Laveille C; Tranchand B; Mentré F; Lemenuel-Diot A; Girard P
    Br J Clin Pharmacol; 2007 Nov; 64(5):603-12. PubMed ID: 17711538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis.
    Gobburu JV; Chen EP
    J Pharm Sci; 1996 May; 85(5):505-10. PubMed ID: 8742942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.
    Peigné S; Fouliard S; Decourcelle S; Chenel M
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):29-43. PubMed ID: 26578442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.